NCT03433534View on ClinicalTrials.gov

Study of the Concentration-effect Relationship of Nivolumab in Patients With Kidney or Lung Cancer

CompletedOBSERVATIONAL
Enrollment

64

Participants

Timeline

Start Date

January 29, 2018

Primary Completion Date

December 21, 2018

Study Completion Date

December 21, 2018

Conditions
Kidney CancerLung Cancer
Interventions
OTHER

Pharmacokinetic of Nivolumab

Nivolumab residual concentration is measured 14 days after administration of nivolumab 3 mg/kg as an intravenous infusion just before the new administration.

Trial Locations (2)

37044

Medical oncology department, University Hospital, Tours, Tours

Pneumology department, University Hospital, Tours, Tours

All Listed Sponsors
lead

University Hospital, Tours

OTHER

NCT03433534 - Study of the Concentration-effect Relationship of Nivolumab in Patients With Kidney or Lung Cancer | Biotech Hunter | Biotech Hunter